ADC Therapeutics
He is a member of the scientific advisory board of France’s National Cancer Institute and a board member of the European Organisation of Research and Treatment of Cancer. From 2008 to 2015, Dr. Bizzari served as Executive Vice President, Group Head of Clinical Development Oncology at Celgene Corporation. Prior to that, he held various senior clinical development positions at Sanofi S.A., Aventis, and Rhône-Poulenc. In addition to the rboard of directors, Dr. Bizzari also serves as a member of the boards of directors of Halozyme Therapeutics, Inc., Oxford BioTherapeutics Limited, and Nordic Nanovector ASA, and previously served on the boards of directors of Transgene S.A., Onxeo SA, and Compugen Limited. Dr. Bizzari holds an M.D. from Nice Medical School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
ADC Therapeutics
2 followers
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.